Thanks a lot. It's with great pleasure.
We're here to present our Q3 report from Cantargia. It's been an exciting period with a rich news flow. And if we quickly summarize the news flow during or after this period, we've seen that we made progress in both of our clinical programs, the Nadunolimab and CAN10 programs. Some of the material events have been that the FDA gave us clearance to start a leukemia study, which is also fully funded by a grant from the US Ministry of Defence. And we got the first results in the randomized phase 2 trial, more clearly defining when to expect. And it's going to be in the first half of 2025, so obviously something to look forward to later on.
Uh, we presented new clinical data first at the ESMO Congress on Nadunolimab combination therapy after relapse on PD1 inhibitor therapy. And that shows some very exciting data points.
And we'll go through that in a second. And we also conducted a number of clinical trials that were initiated in 2021. But due to changing market conditions, we altered our strategy and did not complete those clinical trials. But now that the results are ready, we can see that we have clear support in our ongoing strategies from those trials. Uh, the CAN10 program, then, is not in cancer. So now we're switching gears towards immunological or inflammatory diseases. And a lot of focus has been on the Phase 1 clinical trials, where we have made progress. For instance, the safety analysis has looked very good. And an independent committee recommended continuing to the multiple dosing phase, which then started in September. Uh, but we also had lots of positive results regarding biomarkers and pharmacodynamic effects in the phase one clinical trial. Again, this is something we'll go through, and we presented more results on CAN10 in diseases at the conference. And then uh, very importantly, obviously, based on all this progress, we are now committed to continue to develop both programs. And, we are now announcing a rights issue, which is obviously pending FDA approval, but we will go through that in a second as well.
So, then to take you through our program. So, the CAN10 program is uh, it's a unique molecule, CAN10. It is designed to basically inhibit three different inflammatory and disease-promoting cytokine systems at the same time. So it's the IL1, IL33, and IL36 systems. And uh, the inhibition is very potent.
It binds with picomolar affinity and has, as I said, shown very good effects on blocking cytokines, but also very good effects in various in vivo models of both inflammatory and fibrotic diseases. And the lead indication we're going through right now is a skin disease called Hidradenitis Suppurativa.
It is quite common. It affects about 1% of the Western population, and it starts as inflammation in the hair follicles, which then further progresses into something called draining tunnels, which are on the inside of the skin and cause severe problems and pain. And these patients are treated with antibiotics or steroids in the early stages. And once they're not responding to those, an antibody therapy is used; nevertheless, only 50% of patients respond to those therapies, and in the end of the day, they will stop responding and the disease will progress to more serious stages. So we believe that this is truly a great opportunity for a compound like CAN10.
And we are even more encouraged because there is clinical evidence suggesting that both IL-1 blockade and IL-36 blockade have an impact on the disease. So if we benchmark to the IL-36 receptor-blocking antibody Spesolimab from Boehringer Ingelheim, there has been a clear effect, as you can see up to the right on this slide, on the draining tunnels, which are a severe problem of this disease. Uh, but also if you look down to the right corner, you can see that there is an antibody called Lutikizumab from AbbVie, which is targeting another part of the disease-promoting cytokines. Meanwhile, this system has a good effect on the inflammatory part of the disease. So as CAN10 is blocking both IL-36 and IL-1, we believe that we have a truly unique opportunity to design something that works much better. And to simplify this, the IL-1 receptor blockade or the IL-1 cytokine blockade will block the inflammation as proved by AbbVie, and the IL-36 receptor blockade will have a strong effect on the draining tunnels and potentially a little bit more. More speculatively, the IL-33 blockade, which we have also built into CAN10, will block the itch component, which is also a serious part of HS. So we are super enthusiastic about taking this drug forward from Phase 1 and into Phase 2 in HS.
And we believe that we're ready to do that during the second half of next year.
Uh, so then quickly on what we've seen so far. So the CAN10 results previously presented to date are all from single-dose studies. Uh, and to summarize, we've observed very, very good safety results. So we have no safety signals, which is very encouraging.
Uh, but we do see that the drug is biologically active. So if you look down to the left, you can see that the drug binds to two types of immune cells, which are driving diseases like monocytes and neutrophils. So basically, the higher the dose, the higher the number will be in the said cohort. And you can see that with increasing doses, we get increased binding. What's really interesting is that if you look to the right, when we analyze these immune cells in whole blood after treatment with CAN10, we can see that they are no longer responding to cytokines like IL-36. And again, it's dependent on the dosing. So the higher the dose we give, the better the effect we will have.
So at the end of the day, we believe that we have a drug which is essentially turning off the inflammatory properties of these disease-promoting cells, and this is generating a lot of interest. So then moving into our second program, Nadunolimab. So IL1RAP, which is a target for both CAN10 and Nadunolimab, is overexpressed on a large number of solid tumors. And therefore, we believe that we have a unique opportunity to treat cancer as well.
And IL1RAP is not only expressed on the cancer cells, but it's also found on immune cells and fibroblasts in the tumor microenvironment, and we are not going to do a deep dive into all the data we have. We have treated more than 300 patients so far, and we present the data from more than 200. But some of the strongest data has been observed in pancreatic cancer. And here, we treated patients in the first line setting.
So basically, patients that are newly diagnosed with pancreatic cancer, which has spread in the body, have a poor prognosis and are typically treated with chemotherapy like gemcitabine and Abraxane. And what we do see is that in the total population, we have a very positive effect. But we've conducted a more sophisticated analysis to determine if there are higher or lower levels of IL1RAP in the tumor tissue. And interestingly, it's really the patients with the high values or levels of IL1RAP which are driving the response here, which you can see both to the right in the waterfalls, where, let's say, the best decreases in tumor size are observed in the IL1RAP high group. And also to the left where you look at the survival, which is about 14.2 months, versus 10.6 months in the high IL1RAP group versus the low group. And interestingly, IL1RAP is linked to worse prognosis. And it's also linked to specific KRAS mutations which are supposed to drive the disease. So again, this is a really, really important finding.
And we're now going forward into randomized trials. And the exact design is not ready yet.
But it's going to be a Phase 2 and Phase 3 trial where we will include the diagnostic method to really select the patients with high IL1RAP, to maximize the chances of a positive result and minimize the risk in the high IL1RAP group in the first-line setting. We estimate that around 60% of the patients, so it's a significant group where we can make a difference. Another exciting observation is that Nadunolimab, when added to chemotherapy, shows significant results.
With chemotherapy, you have to be really cautious because it is really on the borderline.
Of what the patient can cope with. And interestingly, we have seen when we add Nadunolimab. That we actually increase tolerability. One of the side effects of chemotherapy is neuropathy. Neuropathy. And we see that when we add Nadunolimab, the patients experience less neuropathy than you would expect from historical chemotherapy controls. And we also see that there is a dose response here. So, the higher dose levels of Nadunolimab, the more pronounced this effect is. And you can see that to the right. And this fits extremely well with our mechanism of action, where immune cells that accumulate in the nerves are contributing to this really, really horrible side effect. And we are very excited to continue to do this.
And we have not only seen these effects with Abraxane in the study, but we have also seen them later on with oxaliplatin in the later trials that were recently presented, but also with the next generation chemotherapy, which is antibody-drug conjugates. We have good reasons to believe that we can have similar effects. So, this is definitely a finding with very high potential future value. And finally, the data concerning lung cancer. So this is obviously a busy slide. But the key point here is that patients who have been treated with the PD1 inhibitor. So these are lung cancer patients treated with PD-1 inhibitors, which is really standard first-line therapy. They experience changes in the tumor microenvironment that make them more likely to be sensitive to Nadunolimab. And you can see on the right, when you examine all these tumor tissues, that these patients have a significantly higher number of IL1RAP-containing immune cells in the tumor microenvironment. And they also have lots of other immune cells which should react positively to Nadunolimab treatment. And the clinical results we then observed in this group are very encouraging. With more than a 90% response rate as well as 26 months overall survival in the non-squamous second-line non-small cell lung cancer group.
So clearly, this result is creating interest and gives us a way forward in the lung cancer area as well.
So in summary, Nadunolimab.
So we treated more than 300 patients. We have a pretty solid database with robust data, and we are starting to see more and more data that allows us to identify the subgroups both in pancreatic cancer and lung cancer, which are really the key patients to target. And we are developing diagnostic tests to be used.
And we have also seen that the safety is good, and we actually counteract neuropathy.
So with that, we're in a good position.
But we're also generating more data, both in triple-negative breast cancer and leukemia through the ongoing and upcoming trials. So it's a very exciting future for this program as well.
So by that, I'm finishing off with what you as an investor can expect from milestones.
So in pancreatic cancer, there is the upcoming trial in the high IL1RAP subgroup starting the second half of next year.
And in triple-negative breast cancer, we expect the first randomized data set with Nadunolimab, and top-line data will be presented later on during H1 next year.
Uh, the leukemia trial. We hope to include the first patients during Q4 this year, and it's in collaboration with MD Anderson, as we previously discussed.
And then the CAN10 program where recruitment is ongoing for the MAD phases. We expect the Phase 1 data to come sequentially during H1, with final data during Q2 next year, and then starting with Phase 2 during the second half of 2025. So by that, I've covered where we are with the products and what's in the near future, and hand over to Patrick to go through the finances as well as the upcoming rights issue.